These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 25836937)

  • 1. First-line treatment and prognostic factors of metastatic bladder cancer for platinum-eligible patients.
    Abida W; Bajorin DF; Rosenberg JE
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):319-28, ix-x. PubMed ID: 25836937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line treatment of metastatic disease: cisplatin-ineligible patients.
    Cathomas R; De Santis M; Galsky MD
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):329-40, x. PubMed ID: 25836938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum analogue combination chemotherapy: cisplatin, carboplatin, and methotrexate in patients with metastatic urothelial tract tumors. A phase II trial with evaluation of prognostic factors.
    Sengeløv L; Nielsen OS; Kamby C; von der Maase H
    Cancer; 1995 Nov; 76(10):1797-803. PubMed ID: 8625050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evidence for the first-line treatment of advanced urothelial carcinoma: Current paradigms and emerging treatment options.
    Koufopoulou M; Miranda PAP; Kazmierska P; Deshpande S; Gaitonde P
    Cancer Treat Rev; 2020 Sep; 89():102072. PubMed ID: 32769039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
    Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epicure: a European epidemiological study of patients with an advanced or metastatic Urothelial Carcinoma (UC) having progressed to a platinum-based chemotherapy.
    Houédé N; Locker G; Lucas C; Parra HS; Basso U; Spaeth D; Tambaro R; Basterretxea L; Morelli F; Theodore C; Lusuardi L; Lainez N; Guillot A; Tonini G; Bielle J; Del Muro XG
    BMC Cancer; 2016 Sep; 16(1):752. PubMed ID: 27664126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Prediction by Baseline Systemic Immune-inflammation Index (SII) and its Changes During First-line Platinum-based Treatment in a Caucasian Population of Patients With Metastatic Urothelial Carcinoma (MUC).
    Palacka P; Slopovsky J; Obertova J; Chovanec M; Rejlekova K; Sycova-Mila Z; Kollarik B; Mardiak J; Mego M
    Anticancer Res; 2021 Nov; 41(11):5749-5759. PubMed ID: 34732448
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens.
    Bellmunt J; Choueiri TK; Fougeray R; Schutz FA; Salhi Y; Winquist E; Culine S; von der Maase H; Vaughn DJ; Rosenberg JE
    J Clin Oncol; 2010 Apr; 28(11):1850-5. PubMed ID: 20231682
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
    Galsky MD; Krege S; Lin CC; Hahn N; Ecke T; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3020-6. PubMed ID: 23720197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the Treatment of Metastatic Urothelial Carcinoma.
    Bukhari N; Al-Shamsi HO; Azam F
    ScientificWorldJournal; 2018; 2018():5682078. PubMed ID: 29977169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?
    Buti S; Ciccarese C; Zanoni D; Santoni M; Modena A; Maines F; Gilli A; Bria E; Brunelli M; Rimanti A; Cascinu S; Ardizzoni A; Tortora G; Massari F
    Future Oncol; 2015; 11(1):107-19. PubMed ID: 25572786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monotherapy with intravenous vinflunine in patients with advanced or metastatic urothelial cancer after failure of a platinum-containing regimen: a retrospective analysis of German routine data.
    Hegele A; Goebell P; Matz U; Neuhaus T
    Urol Int; 2014; 92(2):174-9. PubMed ID: 24334998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New developments in first- and second-line chemotherapy for transitional cell, squamous cell and adenocarcinoma of the bladder.
    De Santis M; Bachner M
    Curr Opin Urol; 2007 Sep; 17(5):363-8. PubMed ID: 17762632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Open-Label, Randomized Phase II Trial of Personalized Peptide Vaccination in Patients with Bladder Cancer that Progressed after Platinum-Based Chemotherapy.
    Noguchi M; Matsumoto K; Uemura H; Arai G; Eto M; Naito S; Ohyama C; Nasu Y; Tanaka M; Moriya F; Suekane S; Matsueda S; Komatsu N; Sasada T; Yamada A; Kakuma T; Itoh K
    Clin Cancer Res; 2016 Jan; 22(1):54-60. PubMed ID: 26581246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Future directions and targeted therapies in bladder cancer.
    Sonpavde G; Jones BS; Bellmunt J; Choueiri TK; Sternberg CN
    Hematol Oncol Clin North Am; 2015 Apr; 29(2):361-76, x. PubMed ID: 25836940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatment of metastatic bladder cancer and future directions.
    Lei AQ; Cheng L; Pan CX
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1851-62. PubMed ID: 22117153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy.
    Kim KH; Do IG; Kim HS; Chang MH; Kim HS; Jun HJ; Uhm J; Yi SY; Lim DH; Ji SH; Park MJ; Lee J; Park SH; Kwon GY; Lim HY
    APMIS; 2010 Dec; 118(12):941-8. PubMed ID: 21091775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.